News

In order to fund selected research projects over the course of the five year agreement, the organizations will each contribute about $2m. The deal is the result of

According to the firms, the small molecule HM71224 is ready to enter Phase II and will be examined for the potential treatment of rheumatoid arthritis, lupus, lupus nephritis,

The joint commercialization deal is in line with Daiichi’s strategy to expand its US portfolio through strategic alliances, in addition to its internal research and development (R&D) and

These antibodies are directed to DR5, also called as Trail Receptor 2 (TRAIL-R2), an emerging cancer target. As part of the deal, Genmab will pay iDD Biotech an

Carcinoid syndrome is a serious condition caused by symptomatic neuroendocrine tumors, which produce large amounts of serotonin. Telotristat etiprate is an oral, small-molecule inhibitor of tryptophan hydroxylase (TPH)

The drug is approved for children with CF who have one of ten mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (G551D, G1244E, G1349D, G178R, G551S,

The new products will be developed from Sorrento’s G-MAB library against neoepitopes of tumor-specific antigens discovered using NantWorks’ pan-omics based, precision medicine approach. As part of the deal,

Consisting of an anti-inflammatory drug conjugated to a biopolymer, the new product candidate has been developed using Synartro’s drug delivery technology to create locally acting pharmaceuticals with limited

SPI-026 was discovered by Dr Edda Speikerkoetter and is being developed with the help of Dr Roham Zamanian at Stanford University. The company said that SPI-026 prevented the